2018
P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy
Woodard G, Wang S, Kratz J, Haro G, Gubens M, Blakely C, Jahan T, Jones K, Mann M, Jablons D. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy. Journal Of Thoracic Oncology 2018, 13: s835. DOI: 10.1016/j.jtho.2018.08.1487.Peer-Reviewed Original Research
2017
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer
Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2017, 19: 58-64. PMID: 28645632, DOI: 10.1016/j.cllc.2017.05.015.Peer-Reviewed Original ResearchConceptsHigh-risk patientsDisease-free survivalLow-risk patientsAdjuvant chemotherapyNational Comprehensive Cancer Network guidelinesCell lung cancer patientsMolecular profilingEarly-stage NSCLCHigh-risk criteriaLog-rank analysisCell lung cancerHigh-risk designationLung cancer patientsKaplan-Meyer estimatesAdjuvant treatmentNonsquamous NSCLCOccult metastasesStage IAStage NSCLCAdjuvant interventionClinicopathologic characteristicsComplete resectionConsecutive patientsDisease recurrenceNCCN criteria
2014
Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer
Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2014, 15: 426-432. PMID: 25258195, DOI: 10.1016/j.cllc.2014.07.004.Peer-Reviewed Original ResearchConceptsHigh-risk patientsLow-risk patientsStage IBNCCN criteriaNCCN guidelinesRisk stratificationHigh-risk clinicopathologic featuresEarly-stage NSCLC patientsAdjuvant chemotherapy recommendationsMonths of patientsMolecular risk stratificationCell lung cancerIdentification of patientsSmall cohort studiesMolecular risk assessmentBlinded chart reviewMolecular assaysAdjuvant chemotherapyChemotherapy recommendationsNonsquamous NSCLCStage IAChart reviewCohort studyNSCLC patientsRecurrence outcomes